Is Neogen Stock Outperforming Its Rivals?
Neogen’s (NEOG) stock notably underperformed over the past year, but how does it measure up against rapidly scaling peers? A closer look reveals negative LTM revenue growth, operating, and free cash flow margins, along with a negative PE ratio. This indicates significant profitability challenges, suggesting limited upside without a fundamental turnaround.
- NEOG’s -2.3% operating margin (vs. ZTS’s 37.6%) signals operational inefficiencies impacting profitability.
- NEOG’s -2.8% LTM revenue growth, lagging peers, suggests market share loss or weak product demand.
- NEOG’s 25.7% stock decline and -2.0 P/E signal investor concern over profitability and future earnings potential.
Here’s how Neogen stacks up across size, valuation, and profitability versus key peers.
| NEOG | MRK | ZTS | IDXX | ELAN | WST | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.1 | 276.9 | 56.2 | 57.1 | 11.5 | 19.9 |
| Revenue ($ Bil) | 0.9 | 64.2 | 9.4 | 4.2 | 4.6 | 3.0 |
| PE Ratio | -2.0 | 14.5 | 21.2 | 55.5 | 320.7 | 40.4 |
| LTM Revenue Growth | -2.8% | 1.7% | 2.7% | 8.4% | 3.1% | 4.9% |
| LTM Operating Margin | -2.3% | 34.9% | 37.6% | 31.3% | 5.2% | 20.9% |
| LTM FCF Margin | -0.4% | 20.3% | 23.8% | 22.6% | 7.7% | 12.6% |
| 12M Market Return | -25.7% | 15.3% | -22.1% | 64.8% | 101.2% | -18.0% |
For more details on Neogen, read Buy or Sell NEOG Stock. Below we compare NEOG’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Freeport-McMoRan Earnings: The Good, the Bad, and the Grasberg
- Can Newmont Keep Riding The Gold Rally Into 2027?
- Intel, Lam, KLA: Will Musk’s $120B Terafab Boost These Stocks?
- Get Paid 10% To Buy NVDA At A 30% Discount, Here’s How
- How CVS Health’s Transformation Is Facing A Hard Valuation Floor
- Is UBER Stock Undervalued At $80?
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| NEOG | -2.8% | -3.2% | 12.4% | 56.0% | |
| MRK | 1.7% | – | 6.7% | 1.4% | 21.7% |
| ZTS | 2.7% | – | 8.3% | 5.7% | 3.9% |
| IDXX | 8.4% | – | 6.5% | 8.7% | 4.7% |
| ELAN | 3.1% | – | 0.5% | 0.1% | -7.4% |
| WST | 4.9% | – | -1.9% | 2.2% | 2.0% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| NEOG | -2.3% | -0.2% | 6.3% | 4.6% | |
| MRK | 34.9% | – | 31.5% | 4.9% | 30.8% |
| ZTS | 37.6% | – | 36.6% | 35.9% | 36.2% |
| IDXX | 31.3% | – | 29.0% | 30.0% | 26.7% |
| ELAN | 5.2% | – | 5.7% | 7.4% | 8.7% |
| WST | 20.9% | – | 20.4% | 24.0% | 26.4% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| NEOG | -2.0 | -1.4 | -279.0 | -166.1 | |
| MRK | 14.5 | – | 15.6 | 691.5 | 19.0 |
| ZTS | 21.2 | – | 23.0 | 32.1 | 43.8 |
| IDXX | 55.5 | – | 62.8 | 40.6 | 68.3 |
| ELAN | 320.7 | – | 33.1 | -4.8 | -93.3 |
| WST | 40.4 | – | 40.8 | 41.0 | 44.7 |
Still not sure about NEOG stock? Consider portfolio approach.
Why Stock Pickers Win More With Multi Asset Portfolios
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices